Analyst predicts strong growth for diabetic macular edema market

31 August 2023

The diabetic macular edema (DME) market in the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow from $5.4 billion in 2021 to $9.6 billion in 2031.

The market expansion will be driven by the launch of longer-acting anti-vascular endothelial growth factor (VEGF) therapies to treat patients with DME, an increase in the number of people with DME, and drugs with new mechanisms of action, new routes of administration, or both, data and analytics company GlobalData forecasts.

GlobalData’s latest report, “ Diabetic Macular Edema: Seven-Market Drug Forecast and Market Analysis - Update,” reveals that anti-VEGF therapies will remain the dominant treatment modality for DME during the forecast period. This theme is observed both in currently marketed products and late-stage pipeline products for DME, with companies focusing on reducing the treatment burden associated with these therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK